Clinical Trial: Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE)

U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801119) titled 'Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE)' on Jan. 15.

Brief Summary: This is an investigator-initiated trial designed to evaluate the safety, and efficacy of HN2301 in Relapsing and refractory systemic lupus erythematosus

Study Start Date: Feb., 2025

Study Type: INTERVENTIONAL

Condition: Systemic Lupus Erythematosus

Intervention: DRUG: HN2301 injection

Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd

Disclaimer: Curated by HT Syndi...